FDA seeks more info on Cervarix

Share this article:

GlaxoSmithKline said approval of Cervarix will be delayed in the US after FDA regulators requested more information on the vaccine in a “complete response letter” to the drugmaker.

Complete response letters are usually issued by the agency when the review of a file is complete and questions remain to be answered prior to approval.

GSK did not say publicly what questions were asked in the letter.

"We have already started addressing the questions and will be engaged in discussions with the FDA to finalize our responses," said Barbara Howe, MD, VP and director, North American vaccine development, GlaxoSmithKline in a statement. "Our discussions with the agency continue to be positive and constructive, and we are working diligently to resolve any outstanding questions to bring Cervarix to the US market."

Cervarix is already approved in 45 countries, including the 27 member countries of the European Union, Mexico and Australia.

GSK's vaccine competes with Merck's Gardasil, which has been available for a year in the US and is prescribed for use by girls and women aged nine to 26.

In early trading in New York, GSK shares fell 80 cents, or 1.5%, to $52.20, while Merck shares rose 88 cents, or 1.5%, to $60.45.

Gardasil brought in $418 million in sales for Whitehouse Station, NJ-based Merck in the third quarter.

Lehman Brothers analyst Tony Butler last year estimated Gardasil may generate $3 billion in peak annual sales for Merck.
 
Cervical cancer is the second-most common malignancy among women after breast cancer and kills 250,000 a year worldwide, according to the World Health Organization.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...